Treatment of Oligometastatic Disease
Mary-Ellen Taplin, MD, discusses the evolving treatment landscape for oligometastatic prostate cancer.
Read MoreSelect Page
Posted by Mary-Ellen Taplin, MD | Mar 2025
Mary-Ellen Taplin, MD, discusses the evolving treatment landscape for oligometastatic prostate cancer.
Read MorePosted by Daniel P. Petrylak, MD | Mar 2025
Arlene O. Siefker-Radtke, MD, explores the evolving role of erdafitinib in treating FGFR3-altered urothelial carcinoma.
Read MorePosted by John Sylvester, MD, FABS | Mar 2025
John Sylvester, MD, FABS, delves into the historical evolution, techniques, and efficacy of brachytherapy in prostate cancer management.
Read MorePosted by Shilpa Gupta, MD | Mar 2025
Shilpa Gupta, MD, explores the evolving treatment paradigm in metastatic urothelial carcinoma following the EV-302 trial.
Read MorePosted by Adam B. Murphy, MD, MBA, MSCI | Mar 2025
Adam B. Murphy, MD, MBA, MSCI, delivers a compelling 12-minute talk on prostate cancer risk assessment in black men.
Read More